Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck

Oncology

Volumn 60, Issue 1, 2001, Pages 66-71

  Pivot, Xavier ^a   Cals, L ^b   Cupissol, D ^c   Guardiola, E ^a   Tchiknavorian, X ^b   Guerrier, P ^c   Merad, L ^b   Wendling, J L ^b   Barnouin, L ^d   Savary, J ^d   Thyss, A ^a   Schneider, M ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b Hopital Font Pre   (France)

^c CENTRE VAL D AURELLE   (France)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Carboplatin; Chemotherapy; Head and neck squamous cell carcinoma; Paclitaxel; Recurrence

Indexed keywords

CARBOPLATIN; CIMETIDINE; DIPHENHYDRAMINE; GRANISETRON; ONDANSETRON; PACLITAXEL; PREDNISONE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TUMOR RECURRENCE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 17744372477     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055299     Document Type: Article

References (16)

1. Head and neck cancer
2. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group
3. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study
4. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study
5. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group
6. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
7. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390)
8. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
9. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma
10. Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: A clinical phase I study
11. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck
12. Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial
13. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: A preliminary report
14. Chemotherapy for relapsed head and neck cancer: Paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study
15. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group
16. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers